Finance Watch: NGM Reemerges With $122m During Post-July 4th VC Mega-Round Boom

Explosion Of $100m-Plus Financings In July

Private Company Edition: After its acquisition by an investor earlier this year, NGM Bio has raised a $122m series A round, adding to a recent surge in large venture capital financings. Also, Vanqua Bio disclosed $45m in new funding and Renalys completed a $38.4m series A.

Finance Watch Private Company
• Source: Shutterstock

NGM Biopharmaceuticals, Inc. added its name to a long and growing list of biopharmaceutical companies raising $100m-plus venture capital mega-rounds with a $122m series A round announced on 17 July. It is NGM Bio’s first financing since February, when it announced that its largest shareholder, The Column Group (TCG), would acquire the then-public company and take it private.

Post-July 4th VC Mega Rounds 

Billions of venture capital dollars have surged into biopharma firms during the first few weeks of July, including Flagship Pioneering’s announcement that it has raised $3.6bn for two new VC funds. For details on this and other large post-fourth of July VC deal announcements, see these Scrip articles:

Flagship Plans To Distribute New Fund To About Two Dozen Companies

Cardurion Raises $260m To Advance First-In-Class Cardiovascular Drugs

Scorpion Sinks Pincers Into $150m Funding Round For PI3K Inhibitor

ASCO Data Are Catalyst For $150m CatalYm Cash Boost

ADC-Focused Myricx Moves To Next Phase With £90m ($114m) Cash Injection

Investors Back Asceneuron With $100m To Rival Lilly In Alzheimer’s Oral Drug Class

Mega-rounds have driven a surge in venture capital fundraising in 2024, with biopharma companies raising $6.53bn in the first quarter...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

In Brief: Sanofi Cements Support For Adagene

 
• By 

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

Stock Watch: Syncona’s Wild Ride Exposes Suspect Strategies

 
• By 

A track record of positive portfolio performance is described as an investment management skill. Taking difficult divestment decisions early, in challenging markets and outperforming benchmarks, are hallmarks of this skill. Syncona and Woodford Patient Capital offer useful case studies.

More from Business

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By 

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By 

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.